Literature DB >> 16628667

Tailoring antiviral therapy in hepatitis C.

Gary L Davis.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16628667     DOI: 10.1002/hep.21194

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

1.  Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.

Authors:  G Colucci; J Ferguson; C Harkleroad; S Lee; D Romo; S Soviero; J Thompson; M Velez; A Wang; Y Miyahara; S Young; C Sarrazin
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

Review 2.  Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

Authors:  Brian L Pearlman
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress.

Authors:  Misao Kuroki; Yasuo Ariumi; Masanori Ikeda; Hiromichi Dansako; Takaji Wakita; Nobuyuki Kato
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

Review 4.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.